Charmacy Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Charmacy Pharmaceutical has a total shareholder equity of CN¥592.2M and total debt of CN¥948.8M, which brings its debt-to-equity ratio to 160.2%. Its total assets and total liabilities are CN¥3.3B and CN¥2.7B respectively. Charmacy Pharmaceutical's EBIT is CN¥129.4M making its interest coverage ratio 2.5. It has cash and short-term investments of CN¥417.4M.
Key information
160.2%
Debt to equity ratio
CN¥948.84m
Debt
| Interest coverage ratio | 2.5x |
| Cash | CN¥417.41m |
| Equity | CN¥592.15m |
| Total liabilities | CN¥2.68b |
| Total assets | CN¥3.27b |
Recent financial health updates
These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well
Oct 25
Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?
May 02Recent updates
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased
May 13There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump
Apr 24Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 19These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well
Oct 25If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity
Sep 17Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?
May 02What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Mar 15Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?
Feb 17We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide
Jan 27Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture
Jan 09What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us
Dec 22
Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years
Nov 29Financial Position Analysis
Short Term Liabilities: 2289's short term assets (CN¥2.8B) exceed its short term liabilities (CN¥2.6B).
Long Term Liabilities: 2289's short term assets (CN¥2.8B) exceed its long term liabilities (CN¥40.5M).
Debt to Equity History and Analysis
Debt Level: 2289's net debt to equity ratio (89.7%) is considered high.
Reducing Debt: 2289's debt to equity ratio has increased from 108.8% to 160.2% over the past 5 years.
Debt Coverage: 2289's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 2289's interest payments on its debt are not well covered by EBIT (2.5x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 06:52 |
| End of Day Share Price | 2025/01/28 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Charmacy Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|